Citation: | SHISuo-fang, FANGZhu-yuan, XIONGKan, YEDe-liang, WANGWei-min, CHENYong-chang, WUDi, LIYun-ze, ZHANGYue-qing, CUILei, CHENMing-qi, WANGBo-han. Clinical Observation of the Rehabilitation Formula for Banking up Earth to Generate Metal in Treating COVID-19 Patients with Deficiency of Lung and Spleen Syndrome in the Recovery Stage[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(3): 281-285. |
[1] |
国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第六版)[S].中国感染控制杂志,2020,19(2):192-195.
|
[2] |
刘宝东.新型冠状病毒感染的肺炎发病机制和治疗策略:从肺癌免疫检查点抑制剂相关不良事件说开去[J].中国胸心血管外科临床杂志,2020,27(2):2.
|
[3] |
史锁芳,刘清泉.从“江夏方舱中医模式”探讨中医药在新型冠状病毒肺炎治疗中的价值[J/OL].江苏中医药.[2020-04-30].https://doi.org/10.19844/j.cnki.1672-397X.2020.00.008.
|
[4] |
李灿东,吴承玉.中医诊断学[M].北京:中国中医药出版社,2012:197-198.
|
[5] |
张伯礼,薛博瑜.中医内科学[M].2版.北京:人民卫生出版社,2002:14.
|
[6] |
中药新药临床研究指导原则[M].北京:中国医药科技出社,2002:364,392.
|
[7] |
潘芳,庞博,梁腾霄,等.新型冠状病毒肺炎中医防治思路探讨[J/OL].北京中医药.[2020-04-30].http://kns.cnki.net/kcms/detail/11.5635.R.20200217.1519.002.html.
|
[8] |
黄帝内经素问[M].北京:人民卫生出版社,2018:262.
|
[9] |
EKDAHL KN, PERSSON B, MOHLIN C, et al. Interpretation of serological complement biomarkers in disease[J].Front Immunol, 2018,9:2237.
|
[10] |
胡家光,蒋忠胜,李旭,等.新型冠状病毒肺炎患者16例外周血T淋巴细胞亚群的变化及意义[J/OL].广东医学.[2020-04-30].https://kns.cnki.net/KCMS/detail/44.1192.r.20200311.1731.002.html.
|
[11] |
侯可可,张娜,李桃,等.新型冠状病毒肺炎不同时期CT表现及中性粒细胞/淋巴细胞比值、T淋巴细胞亚群变化[J].放射学实践,2020,35(3):272-276.
|